Clinical Trials

    Showing 1 - 7 of 7 pulmonary hypertension

    An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension (ASCENT Study) LTI-401

    Status: Enrolling

    Investigator: Mohi Syed

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability ofLIQ861 in subjects who have WHO Group 1 & 3 PH. Cohort A will include approximately 60 subjects who have WHO Group 3 Pulmonary Hypertension associated... Read more >

    DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

    Status: Open Not Enrolling

    Investigator: Meagan Chavarria

    Study Coordinator: Jennifer Lee

    Phone: 713.363.7537

    The purpose of this study is to observe and capture demographic characteristics, treatment patterns, and clinical outcomes of interest for patients with PH-ILD to further clinical understanding of the epidemiological landscape and outcomes of the dis... Read more >

    Pulmonary Artery DenerVation Clinical Study using the Gradient Denervation System in Heart Failure Patients with Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

    Status: Enrolling

    Investigator: Rayan Yousefzai

    Study Coordinator: Jan-Michael Ragunton

    Phone: 346.238.0218

    Characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension... Read more >

    Pulmonary Hypertension Association Registry (PHAR)

    Status: Open Not Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Royanne Holy

    Phone: 713.363.7536

    The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participa... Read more >

    Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

    Status: Enrolling

    Investigator: Sandeep Sahay

    Study Coordinator: Herpreet Sandhu

    Phone: 713.441.5660

    Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). In this study, subjects will undergo a broad range of... Read more >

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

    Status: Enrolling

    Investigator: Zeenat Safdar

    Study Coordinator: Ana Lucia Varon Ocampo

    Phone: 713.363.8024

    Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific background t... Read more >

    TRILUMINATE Pivotal Trial

    Status: Open Not Enrolling

    Investigator: Sachin Goel

    Study Coordinator: Padmaja Naik

    Phone: 713.441.7386

    Brief Summary: The primary objective of this trial is to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or great... Read more >